From the Guidelines
The recurrence rate of pneumothorax, a condition related to pleurisy, can be as high as 50% with chest tube drainage alone, but interventions such as pleurectomy, pleural abrasion, and pleurodesis can reduce this rate. When considering the management of pneumothorax, especially in patients with cystic fibrosis, it's crucial to understand that the condition occurs more commonly in older patients and those with more advanced lung disease, leading to a poor prognosis with a median survival of 30 months 1. The treatment approach for pneumothorax involves observing or aspirating small pneumothoraces without symptoms, while larger pneumothoraces require a chest drain, and in some cases, interventions like partial pleurectomy are considered the treatment of choice for patients with recurrent unilateral pneumothoraces or evidence of bilateral pneumothorax 1. Key factors to consider in the management and prevention of recurrence include:
- The underlying cause of the pneumothorax, such as cystic fibrosis
- The size of the pneumothorax and the presence of symptoms
- The patient's overall health status and lung function
- The potential for contralateral pneumothoraces, which can occur in up to 40% of cases 1
- The role of interventions like pleurectomy, pleural abrasion, and pleurodesis in reducing recurrence rates.
From the Research
Pluresiy Recurrency Rate
- The term "pluresiy recurrency rate" is not clearly defined in the provided studies, but we can discuss the concept of cancer recurrence rates based on the available evidence.
- According to the study 2, epithelial ovarian cancer has a high incidence of complete remissions, but the recurrence rate is also high, with most patients experiencing a continuum of symptom-free periods and recurrence episodes.
- The study 3 found that rates of cancer recurrence were similar among individuals receiving anti-TNF therapy, immune-modulator therapy, or no immunosuppression, with no increase in risk.
- Another study 4 found that the use of anti-TNFα therapy was not associated with recurrent or new primary cancer development in patients with previous cancer, with an adjusted hazard ratio of 0·82 (95% CI 0·61-1·11).
- The incidence of recurrent or new primary cancer development was 30·3 cases (95% CI 24·0-38·2) per 1000 person-years in the anti-TNFα treatment group and 34·4 cases (31·7-37·3) per 1000 person-years in the control group, as reported in the study 4.
- The study 5 discusses the use of anti-inflammatory and antioxidant agents as a therapeutic modality for long-term use in patients diagnosed with several common cancers, including colon cancer and breast cancer, which may help reduce the risk of cancer recurrence.
- The concept of generalizability, as discussed in the study 6, is important when applying research findings to clinical practice, and clinicians must make reasoned decisions about the generalizability of research findings beyond a study population.